What is Leerink Partnrs' Forecast for ABVX FY2025 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for ABIVAX Société Anonyme in a report released on Monday, March 24th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.36) for the year, down from their previous estimate of ($3.00). The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme's FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.26) EPS.

Other research analysts have also recently issued reports about the stock. Citizens Jmp raised shares of ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, ABIVAX Société Anonyme has an average rating of "Buy" and an average target price of $38.00.

ABIVAX Société Anonyme Stock Down 5.0 %

Shares of ABVX traded down $0.32 during mid-day trading on Thursday, reaching $6.11. The company had a trading volume of 39,088 shares, compared to its average volume of 202,669. The firm has a fifty day simple moving average of $6.80 and a 200-day simple moving average of $8.32. ABIVAX Société Anonyme has a fifty-two week low of $5.49 and a fifty-two week high of $16.63.

Remove Ads

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several institutional investors and hedge funds have recently made changes to their positions in ABVX. BNP Paribas Financial Markets increased its stake in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC grew its stake in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after buying an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after acquiring an additional 119,300 shares during the period. GAMMA Investing LLC acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth about $29,000. Finally, R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $36,000. 47.91% of the stock is owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.